Cell Source, Inc. (CLCS)

Cell Source Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	2.6	2.6	2.18	2.7	2.64	1.17
Research & Development	1.58	1.58	2	1.32	1	2.63
Operating Expenses	4.18	4.18	4.18	4.02	3.64	3.81
Operating Income	-4.18	-4.18	-4.18	-4.02	-3.64	-3.81
Interest Expense	-1.05	-1.05	-0.99	-1.36	-0.94	-0.31
Other Non Operating Income (Expenses)	0.01	0.01	-	-	0.02	-0.14
EBT Excluding Unusual Items	-5.22	-5.22	-5.17	-5.38	-4.56	-4.25
Legal Settlements	-0.14	-0.14	-	-	-	-
Other Unusual Items	0.04	0.04	-	-0.09	-0	-0.23
Pretax Income	-5.32	-5.32	-5.17	-5.47	-4.56	-4.48
Net Income	-5.32	-5.32	-5.17	-5.47	-4.56	-4.48
Preferred Dividends & Other Adjustments	1.23	1.23	1.16	0.97	0.88	0.74
Net Income to Common	-6.55	-6.55	-6.33	-6.45	-5.44	-5.22
Shares Outstanding (Basic)	38	38	35	33	29	28
Shares Outstanding (Diluted)	38	38	35	33	29	28
Shares Change (YoY)	8.47%	8.47%	5.19%	13.81%	2.72%	2.83%
EPS (Basic)	-0.17	-0.17	-0.18	-0.19	-0.19	-0.18
EPS (Diluted)	-0.17	-0.17	-0.18	-0.19	-0.19	-0.18
Free Cash Flow	-2.35	-2.35	-3.14	-3.38	-2.77	-2.59
Free Cash Flow Per Share	-0.06	-0.06	-0.09	-0.10	-0.10	-0.09
EBIT	-4.18	-4.18	-4.18	-4.02	-3.64	-3.81

Source: S&P Capital IQ. Standard template.